Tesofensine vs HGH Fragment 176-191
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineFat Loss & Metabolic
HGH Fragment 176-191- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- ~30 minutes
- Admin Route
- Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 250–500 mcg
- Frequency
- Once daily
- 1–3 times daily
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Stacks With
- —
- —